GPR110 promotes progression and metastasis of triple-negative breast cancer

Hye-Jung Nam1,2, Yeon-Ju Kim1,2, Jae-Hyeok Kang1 and Su-Jae Lee1✉

© The Author(s) 2022, corrected publication 2022

Breast cancer is the most common type of cancer in women, and approximately 70% of all breast cancer patients use endocrine therapy, such as estrogen receptor modulators and aromatase inhibitors. In particular, triple-negative breast cancer (TNBC) remains a major threat due to the lack of targeted treatment options and poor clinical outcomes. Here, we found that GPR110 was highly expressed in TNBC and GPR110 plays a key role in TNBC progression by engaging the RAS signaling pathway (via Gas activation). High expression of GPR110 promoted EMT and CSC phenotypes in breast cancer. Consequently, our study highlights the critical role of GPR110 as a therapeutic target and inhibition of GPR110 could provide a therapeutic strategy for the treatment of TNBC patients.

Cell Death Discovery (2022)8:271 ; https://doi.org/10.1038/s41420-022-01053-x

INTRODUCTION

Breast cancer is the most common type of malignant cancer in women [1] and can be divided into subtypes, Luminal, HER2+, and triple-negative breast cancer (TNBC) type. Specifically, TNBC is defined to be receptor non-dependent (estrogen, progesterone receptor, and human epidermal growth factor receptor 2). Also, TNBC is a relatively malignant type compared to other types and is difficult to treat [2]. For TNBC patients, the overall survival rate is remarkably low and indicates a high rate of relapse. Therefore, new therapeutic strategies for the treatment of TNBC are needed.

The RAS family includes the KRAS, HRAS, and NRAS subtypes. KRAS is the most frequent oncogene and accounts for 86% of the RAS family (HRAS and NRAS account for 3 and 11%, respectively) [3]. Extensive studies have shown that KRAS upregulation is associated with various malignancies, including lung adenocarcinoma, ductal carcinoma of the pancreas, colorectal carcinoma, and breast carcinoma [4, 5]. Hyperactivity and upregulation of KRAS are significantly associated with worse survival rates. Therefore, inhibition of KRAS activation is a popular and efficient method for cancer treatment [6].

The defining characteristic of adhesion G protein-coupled receptors (GPCRs) that discriminates them from other GPCRs is their hybrid molecular structure. Adhesion GPCRs contain an exceptionally long extracellular region and a variety of structural domains that facilitate cell and matrix interactions. The general signaling mechanism of GPCR begins by an interaction with the guanine nucleotide protein G protein (Gas, Gq, Gas and Gα12/13) [7]. Several previous studies revealed that some members of the adhesion GPCRs can induce cancer progression by regulating angiogenesis, proliferation, metastasis, and survival through their signaling function [8–10]. A previous study showed that GPR110 accelerates liver fibrosis/cirrhosis progressing through activation of the IL-6/STAT3 pathway, leading to a liver injury and fibrosis microenvironment [11]. Furthermore, high expression of GPR110 predicts the poor prognosis of gastric cancer patients [12]. Despite these initial findings of GPR110, GPR110 are orphan receptors, and their signaling pathways have not been investigated in breast cancer. The mechanism and other physiological functions of GPR110 in cancer are also unclear.

In this study, we demonstrated that GPR110 promotes cancer progression by regulating EMT and cancer stem-like cell (CSC) property. Importantly, the increased level of GPR110 correlated with activation of the KRAS signaling pathway. Collectively, our results reveal that the oncogenic function of GPR110 is an important mechanism, resulting in metastasis and CSC in breast cancer, and suggest that GPR110 is a potential candidate for TNBC target therapy.

RESULTS

GPR110 was highly expressed in TNBC

We performed The Cancer Genome Atlas Program (TCGA) database analysis and gene expression analysis to investigate total adhesion GPCR expression in luminal and basal breast cancer (Supplementary Fig. 1A, B). Among the two types of cancer, basal breast cancer was associated with GPR110 gene enrichment. Also, gene set enrichment analysis (GSEA) revealed that basal breast cancer-related signature gene sets were positively correlated with GPR110 expression levels. Although the expression of GPR116 or ELD1 was found to be more significant than GPR110, additional GEO database and TCGA analysis results showed no significance (Supplementary Fig. 1C–E). Therefore, we found that GPR110 had the most significant difference in expression in basal breast cancer compared to luminal breast cancer through GPCR expression analysis screening. Also, we assumed that the high expression of GPR110 in basal breast cancer would contribute to breast cancer malignancy. To confirm our data, we performed expression analysis of GPR110 using a breast scanner patient tissue array.

1Department of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul, Korea. 2These authors contributed equally: Hye-Jung Nam, Yeon-Ju Kim.
✉email: sj0420@hanyang.ac.kr

Received: 12 November 2021 Revised: 30 December 2021 Accepted: 20 January 2022
Published online: 26 May 2022
The IHC staining revealed that GPR110 expression is significantly higher in TNBC patient tissues (Fig. 1A). Additionally, we performed quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting analysis using different subtypes of breast cancer cell lines. The results showed that GPR110 expression was higher in the TNBC subtype of breast cancer (Fig. 1B, C). Kaplan–Meier survival analysis using the GEO database demonstrated that high levels of GPR110 were associated with a poor prognosis in patients with breast cancer (Fig. 1D). Overall, we found that GPR110 expression was higher in TNBC and was associated with poor prognosis in breast cancer patients.

**GPR110 is a key regulator of the epithelial–mesenchymal transition (EMT) in TNBC**

To determine the effects of GPR110 and associated functional mechanisms, GSEA was performed. We found that EMT signature gene expression levels were positively correlated with GPR110 expression levels (Fig. 2A, B). GPR110 knockdown decreased the migration/invasion potential of cells and the expression of EMT markers (N-cadherin, fibronectin, and vimentin) and EMT regulators (Snail, Slug, Zeb1) (Fig. 2C, D). Similar results were obtained in the MDA-MB231 cells by immunocytochemical (ICC) staining (Fig. 2E). Moreover, the expression levels of GPR110 and EMT signature gene ( Slug or Vimentin) were positively correlated with each other in patients from the TCGA breast cancer clinical cohort (Fig. 2F). To validate our results in vivo, LM1 cells transfected with sh-GPR110 were injected into the fat pad of female NOD/SCID mice (Fig. 2G). In xenograft models, the number of lung metastatic foci and tumor weight were significantly lower in the sh-GPR110 group than in the control group (Fig. 1H). Notably, GPR110 inhibition decreased tumor growth (Fig. S2M, N). Western blotting and RT-qPCR analysis showed that suppression of GPR110 inhibited EMT signature genes and the proliferation marker Ki67 in primary tumor tissues (Fig. 2J, L and Fig. S2O). Immunohistochemical staining also revealed that the EMT signature was significantly muted in the sh-GPR110 group (Fig. 1K). Taken together, our data indicate that GPR110 upregulates EMT features in breast cancer.

**GPR110 promotes breast CSCs**

As previously shown in GSEA (Fig. 2A), it was found that CSC signature gene expression levels had a positive correlation with GPR110 expression. To investigate the molecular function of GPR110 for the CSC features, we performed a sphere formation assay in GPR110-silencing MCF7 cells. The results showed that the GPR110 knockdown group decreased the sphere diameter of a cell compared to the control group (Fig. 3A). Furthermore, FACS analysis showed that overexpressing GPR110 increased the percentage of the stem cell population (CD44+/CD24–) and CD44+/CD24– cells) (Fig. 3B). In vitro limiting dilution assay analysis also showed that stem cell frequency was increased in over-expressing GPR110 cells compared to the control group (Fig. 3C). Additionally, the expression of CSC regulators (CD44, Nanog, Oct4, Sox2) was decreased in GPR110-silencing MDA-MB231 cells (Fig. 3D–F). In addition, analysis of the GEO database for breast cancer patients showed a positive correlation between GPR110 expression and CD44 gene and a negative correlation between GPR110 expression and CD24 gene (Fig. 3G). Also, the sh-GPR110 group decreased the expression of CSC regulators compared to the sh-control group in xenograft tumors (Fig. 3H–J). Taken together, our data indicate that GPR110 upregulates CSC in breast cancer.

**GPR110 induces EMT and CSC features via Gas/RAS pathway in breast cancer**

As reported previously, adhesion GPCRs can activate an associated G protein [13]. The G protein contains subunit α together with a bound GTP, which can then dissociate into intracellular signaling proteins or target functional proteins directly depending on the α subunit type (G_αS, G_αq, G_α12/13). The G protein subunit acting on GPR110 is still not investigated in the mechanism of malignancy of breast cancer. Therefore, we performed western blotting to screen for G-proteins interacting with GPR110 in breast cancer cells. Results indicated that the inhibition of GPR110 decreased Gas-GTP levels compared to that of the other subunit types (Fig. S4A). Furthermore, by performing GSEA, we found that expression of Gas signaling signature genes was positively correlated...
with GPR110 expression (Fig. 4A). Immunoprecipitation analysis and in situ proximity ligation assays indicated that Gα interacted with GPR110 (Fig. 4B–D). In addition, blocking Gα alone or with GPR110 overexpression in MCF7 cells reversed increases in EMT/CSC-related gene expression, invasion/migration potential, and sphere size of colonies (Fig. 4E–H).

To investigate how GPR110 participates in the progression of malignant characteristics, we investigated the biological pathway that GPR110 uses to regulate EMT and CSC. In MDA-MB231 cell lines, we performed signaling pathway screening by inhibiting GPR110 and found that GPR110 regulated the activation of RAS, phospho-Raf1, phospho-MEK1/2, and phospho-ERK1/2 (Fig. S4D, I, J).

Fig. 2 GPR110 is a key regulator of the epithelial–mesenchymal transition in breast cancer. A, B GSEA of hallmark epithelial-to-mesenchymal transition gene signature and stemness maker to GPR110 in breast cancer patients (GSE22516). C Invasion/migration assays were performed after silencing GPR110 in MDA-MB231 cells. D qRT-PCR analysis showing EMT markers and regulators after knockdown of GPR110 in MDA-MB231 cells. E Representative images of ICC staining of Vim, Fn, Slug, and Zeb1 in MDA-MB231 transfected with si-GPR110. F A positive correlation between Slug and GPR110 was observed using the public TCGA database (n = 1247). And a positive correlation between Vim and GPR110 was observed using the public TCGA database (n = 1247). G, H After injection into fat pad of female NOD/SCID mice, the image of mouse lungs and representative image of H&E staining of lung metastasis and the number of lung metastatic foci. I, J qRT-PCR analysis and Western blotting of EMT markers and regulators using mouse tissues. K IHC analysis of EMT markers and regulators in xenograft tumors of mice. Scale bar = 100 μm. β-actin was used as a control for normalization of expression. *p < 0.05, **p < 0.001, ***p = 0.0001 and ****p < 0.0001; ns not significant; determined by two-tailed Student’s t test (95% confidence interval).
GSEA analysis (GSE54326) also indicated that GPR110 levels were positively associated with the expression of signature genes in the RAS signaling pathway. Notably, GSEA analysis (GSE24460) showed that GPR110 positively correlated with KRAS signaling signature genes (Fig. 4K). Therefore, GPR110 can induce EMT and CSC by activating the KRAS pathway, suggesting that it can regulate KRAS hyperactivity that contributes to cancer progression by targeting GPR110. To further confirm these findings, we performed rescue experiments. GPR110 overexpression inhibited the invasive features of cells and EMT-related gene expression, while co-overexpression of GPR110 and KRAS reversed the inhibition. (Fig. 4L–N). Likewise, GPR110 overexpression suppressed the sphere-forming ability of cells and CSC-related gene expression, while overexpression of GPR110 and KRAS resulted in rescue (Fig. 4O–Q). Also, the sh-GPR110 group decreased the expression of RAS activity compared to the sh-control group in xenograft tumors (Fig. 4R). Taken together, these results demonstrate that GPR110 induces EMT and CSC features via Gas/RAS pathway.

**GPR110 indicated a poor prognosis of breast cancer**

Together with the accumulated data, GPR110 was identified to be involved in EMT and CSC through the RAS pathway. This result shows that targeting GPR110 can lead to better survival of metastatic breast cancer patients by regulating cancer progression. Reanalysis of the METABRIC breast cancer database and immunohistochemical staining score also showed that overexpressed GPR110 expression was observed in high-stage and high-grade patients’ tissues (Fig. 5A–D). These contributions of GPR110 to the progression of cancer in GPR110 are associated with poor prognosis of all breast cancer patients, as obtained from Kaplan–Meier analysis of GSE25065 and GSE11121 (Fig. 5E). In addition, when comparing the survival of metastatic breast cancer patients, patients with high GPR110 expression showed a poor prognosis outcome (Fig. 5F). GSEA showed that patients with high GPR110 expression displayed a positive correlation with metastasis and breast cancer progression signature gene sets (Fig. 5G). Consequently, our study demonstrates that GPR110 plays a key role in TNBC progression by engaging the RAS signaling pathway (via Gαs activation) (Fig. 5H). Together, our study highlights the critical role of GPR110 as a therapeutic target. Inhibition of GPR110 could provide a therapeutic strategy for the treatment of TNBC patients.

**DISCUSSION**

Breast cancer is generally treated with surgery including chemotherapy of radiation therapy, or both. Also, hormone receptor-positive cancers are treated with hormone-blocking therapy and they can be identified by the presence of estrogen receptors and progesterone on their surface. ER+ cells depend on estrogen for their growth, so they can be treated with drugs such as tamoxifen or an aromatase inhibitor (e.g anastrozole). In addition, overexpression of HER2 in breast cancer is associated with disease recurrence and poor prognosis and HER2+ cells respond to monoclonal antibody trastuzumab and this has improved the prognosis significantly. However, TNBC does not...
have any of the three receptor types and differs from other types of invasive breast cancer in that they grow and spread faster and have limited treatment options. Outcomes of breast cancer vary depending on the cancer type, and the overall survival rate for TNBC patients is remarkably low.

G-protein coupled receptor 110 (GPR110) belongs to subfamily VI of adhesion GPCRs. In previous studies, it has been reported that GPR110 could promote the invasion and migration of lung and prostate cancer [14]. In addition, GPR110, which is highly expressed in an anti-HER2 therapy-resistant population [15], has a potential role in tumorigenesis. However, the clinical function, mechanism, and/or targets of GPR110 in breast cancer remain unknown.

In our research, we identified that GPR110 can interact with Gas, resulting in the progression of breast cancer. First, we found that GPR110 is highly expressed in TNBC compared to other breast cancer subtypes, using human tissue array and GEO analysis. We also showed that the expression of GPR110 regulates EMT and CSC-like features to induce the metastatic phenotype of breast cancer by performing a GSEA public database analysis. In addition, we found that GPR110 can interact with Gas through GSEA database analysis and co-immunoprecipitation assay. Therefore, we performed invasion/migration and sphere formation assays to identify the ability of GPR110/Gas in breast cancer. The results showed that the cells’ ability to invade and migrate and form...
spheres rapidly increased according to the expression of GPR110 and activation of Gαs. These results reveal the mechanism by which GPR110 regulates EMT and CSCs through Gαs activation. Next, we found that GPR110 was associated with the RAS pathway and was especially correlated with KRAS from the GSEA database analysis. Furthermore, western blotting analysis, RT-qPCR analysis, and animal experiments showed that GPR110 could upregulate RAS activity and its downstream effector activation, such as the Raf and ERK signaling pathways. The results showed that GPR110 has the potential to control EMT and CSCs through active KRAS. Rescue experiments showed that when GPR110 was overexpressed in MCF-7 cells, which represent a luminal type of breast cancer, the expression of EMT and CSC markers and regulators increased, while their expression was inhibited when KRAS expression was knocked down in GPR110-overexpressing MCF-7 cells. Consequently, we found that GPR110 promoted EMT and CSCs through the Gαs-RAS signaling pathway in breast cancer. However, this study has some limitations. The upstream regulator of GPR110 is still unclear. Also, we do not know whether this occurs in other human malignancies. Further studies are required to address these limitations.

In summary, our findings demonstrate the importance of GPR110 in metastatic features and cancer formation in TNBC. We found that GPR110 expression was higher in TNBC compared to luminal breast cancer and that a high expression of GPR110 correlates with poor outcomes. In addition, we found that GPR110 activates KRAS and regulates EMT and CSC in TNBC. In contrast, loss of GPR110 function results in EMT and CSC attenuation and a better outcome prognosis in breast cancer patients. Taken together, targeting the GPR110/Gαs/RAS signaling pathway axis provides an effective strategy and mechanical system to relieve malignancies and improve the poor prognosis of patients with TNBC.

MATERIALS AND METHODS

Cell culture
MDA-MB231, H5578T, BT549, SKBR3, and MCF7 breast cells were obtained from KCLB (Korean cell line bank). HECK293T cells were obtained from American type culture collection (ATCC). MDA-MB231, H5578T, LM1, and HECK293T cell lines were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum (FBS) in the presence of penicillin/streptomycin. MCF7, SKBR3, and BT549 cell lines were maintained in Roswell Park Memorial institutie 1640 medium from Gibco (Grand Island, NY, USA) with 10% FBS in presence of penicillin (100 U/mL)/streptomycin (100 μg/mL).

Chemical reagents and antibodies
Antibodies to pan-RAS (ab52939), H-RAS (ab97488), N-RAS (ab77392), K-RAS (ab137739), Raf1 (ab137435), p-JAK1 (sc-101716), p-ERK1/2 (sc-7383), AKT (sc-5298), STAT3 (sc-482), JAK1 (sc-7228), SRC (sc-8056), OCT4 (sc-9081), SOX2 (ab97959) and β-actin (sc-47778), anti-mouse IgG-HRP, anti-goat IgG-HRP, and anti-rabbit Ig-HRP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to ERK (4695), CD44 (ab157107), Nanog (ab21624), Slug (ab27568), Zeb1 (ab124512), Vimentin (ab8978), and Fibronectin (ab6329) were purchased from Abcam (Cambridge, UK). Antibodies MEK1/2 (8727), p-MEK1/2 (9121), p-JNK (9251), JNK (9252), p-Src (92115), p-AKT (4060), Snail (38795), P38 (9212), p-P38 (92115) and

Fig. 5 GPR110 indicated a poor prognosis of breast cancer. A Graph showing GPR110 expression in stage1 (n = 371), stage2 (n = 571), and stage3 (n = 90) of breast cancers using the database from METABRIC breast cancer databases. B Tissue microarray analysis of GPR110 expression in different stages of breast cancer (left) and the proportion is shown in the graph (right). C Tissue microarray analysis of GPR110 expression in different grades of breast cancer (left) and the proportion is shown in the graph (right). D Kaplan–Meier survival analysis of metastatic breast cancer patients (GSE45255, GSE7390). E Kaplan–Meier survival analysis of metastatic breast cancer patients (GSE45255, GSE7390). F Kaplan–Meier survival analysis of metastatic breast cancer patients (GSE45255, GSE7390). G GSEA of metastasis and cancer progression signature to GPR110 expression in breast cancer patients. H Schematic of GPR110/Gαs/RAS signaling axis mechanism in breast cancer. *p < 0.05, **p < 0.001 and ****p < 0.0001; ns not significant; determined by two-tailed Student’s t-test (95% confidence interval).
p-STAT3 (9131) were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies to GPR110 were purchased from LSbio. Antibodies to Active-RAS were purchased from NewEast, Antibodies to p-Raf1 were purchased from MyBioSource. Antibodies to Ki-67 were purchased from Actis. Antibodies to α-cadherin and β-catenin were purchased from BD biosciences. Vector of GPR110 were purchased from origin (ADGRF1, NM_153840, RC222706).

Western blot analysis
Cell lysates were prepared by extracting proteins with lysis buffer (40 mM Tris–HCl (pH 8.0), 120 mM NaCl, 0.1% Nonidet-P40) which was supplemented with protease inhibitors. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Amersham, Arlington Heights, IL). Blocking the membrane with 5% non-fat dry milk in Tris-buffered saline, and incubated with primary antibodies overnight at 4 °C. Blots were developed with a peroxidase-conjugated secondary antibody, and proteins were visualized with enhanced chemiluminescence (ECL) procedures (Amersham, Arlington, MA, USA). Antibodies to GPR110 were purchased from LSbio. Antibodies to Active-RAS were purchased from NewEast, Antibodies to p-Raf1 were applied to the sections for 1 h. After washing in PBS, biotinylated goat anti-rabbit IgG or anti-mouse IgG antibody was then applied to the sections for 1 h. The color reaction was performed with 3,3'-diaminobenzidine (Vector Laboratories, Burlingame, CA, USA). After counter-staining with hematoxylin and clearing with graded ethanol series and xylene, the sections were mounted with Canada balsam. Images were captured with a DP71 digital imaging system on an IX71 microscope (Olympus, Seoul, Korea).

Human tissue microarray
Human breast cancer tissue microarray samples were obtained from US-Biomax (BR20838). These samples were reviewed by a pathologist to confirm the diagnosis of breast carcinoma and histological grade. Images were captured with a DP71 digital imaging system on an IX71 microscope (Olympus, Seoul, Korea).

Proliferation assay
Cell proliferation efficiency was measured using the Cell Counting Kit-8 (CCK-8, KTA1020, Abbkine) according to the manufacturer’s instructions. Cells (5000 cells/well) were plated in 96-well plates. Afterward, the plates were incubated for an appropriate length of time (24, 48, 72, or 96 h), and the optical density was measured using a microplate reader.

Sphere formation assay
MCF-7 cells (1.5 × 10^5) were plated in 96-well plates at concentrations of 1, 2, 5, and 10 cells per well. Plates were analyzed by light microscopy for the formation of oncospheres, 10–14 days after plating. Positive wells were defined as groups of cells >125 μm in diameter.

Flow cytometric analysis
Flow cytometry was used to detect the CSC markers CD44 and CD24. A total of 1 × 10^5 control cells and GPR110-overexpressing cells were harvested by trypsin digestion, washed, and resuspended in 1× PBS. The cells were incubated with phycoerythrin (PE)-conjugated anti-CD44 monoclonal antibody and FITC-conjugated anti-CD24 antibody (Miltenyi Biotec, Inc., Bergisch Gladbach, Germany) at 4 °C for 30 min. All data were analyzed using the CellQuest software (BD Biosciences) and repeated three times.

GSEA, data set evaluation, and Kaplan–Meier analysis
GSEA was performed on diverse gene signatures by comparing gene sets from either the Molecular Signature Database (MSigDB) or published gene sets.
signatures. To analyze the expression data of GPR110 in breast cancer, previously published microarray data under accession codes GSE20685, GSE5327, GSE58812, GSE14548, GSE12777, GSE21653, GSE2034, GSE11121, GSE5364, GSE4326, GSE24460, GSE22516, GSE7904, GSE12276. TCGA and METABRIC database mRNA expression z-score data sets along the PAM50 gene set were retrieved from UCSC Xena (https://xenabrowser.net/heatmap/) were reanalyzed. To examine the prognostic value of GPR110, patient samples were divided into two groups (low and high expression) for each gene, which was analyzed using the Kaplan–Meier plot program (http://kmplot.com/analysis/) and Breast Cancer Integrative platform (BCIP) program (http://www.omicsnet.org/bcancer/database).

Statistical analysis
All experimental data are presented as the mean ± SD of triplication. Statistical analyses were performed using Student’s t test. Multiple group comparisons were made by analysis of variance using the PRISM 8.0 software (GraphPad). The level of significance is indicated as p < 0.05*.

DATA AVAILABILITY
The data supporting the finding of this study are available from the corresponding author upon reasonable request.

REFERENCES
1. Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134–50.
2. Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293:247–59.
3. Zinatifzadeh MR, Momeni SA, Zarandi PK, Chalbatani GM, Dana H, Mirzaii HR, et al. The role and function of Ras-association domain family in cancer: a review. Genes Dis. 2019;6:378–84.
4. Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020;39:1029–38.
5. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:103–19.
6. Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, et al. Mutational diversity and therapy response in breast cancer: a sequencing analysis in the neoadjuvant GeparSepto Trial. Clin Cancer Res. 2019;25:3986–95.
7. Vizurraga A, Adhikari R, Yeung J, Yu M, Tall GG. Mechanisms of adhesion G protein-coupled receptor activation. J Biol Chem. 2020;295:14065–83.
8. Cao J, Liu X, Yang Y, Wei B, Li Q, Mao G, et al. Decylubiquinone suppresses breast cancer growth and metastasis by inhibiting angiogenesis via the ROS/p53/BAI1 signaling pathway. Angiogenesis. 2015;18:214–27.
9. Ganesh RA, Venkataraman K, Srideshmukh R. GPR56: an adhesion GPCR involved in brain development, neurological disorders and cancer. Brain Res. 2020;1747:147055.
10. Favara DM, Banham AH, Harris AL. A review of ELTD1, a pro-angiogenic adhesion GPCR. Biochem Soc Trans. 2014;42:1658–64.
11. Ma B, Zhu J, Tan J, Mao Y, Tang L, Shen C, et al. Gpr110 deficiency decelerates carcinogen-induced hepatocarcinogenesis via activation of the IL-6/STAT3 pathway. Am J Cancer Res. 2017;7:433–47.
12. Zhu X, Huang G, Jin P. Clinopathological and prognostic significance of aberrant G protein-coupled receptor 110 (GPR110) expression in gastric cancer. Pathol Res Pract. 2019;215:539–45.

AUTHOR CONTRIBUTIONS
H.-J.N., Y.-J.K., and S.-J.L. conceived and designed the experiments; H.-J.N. and Y.-J.K. performed the experiments; H.-J.N. and Y.-J.K. analyzed the data; Y.-J.K. wrote the manuscript.

FUNDING
This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (2019M3E5D1A01069361, 2020R1A4A1018398).

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-022-01053-x.

Correspondence and requests for materials should be addressed to Su-Jae Lee.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected publication 2022